{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:15:37Z","timestamp":1784744137289,"version":"3.55.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"China Association Against Epilepsy, AMPA Mechanism and Antiepileptic Drug Research Grant","award":["CW-B-2021-25"],"award-info":[{"award-number":["CW-B-2021-25"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Perampanel is a promising epilepsy treatment with an innovative mechanism of action. This study was performed to investigate the factors affecting perampanel clearance in a population pharmacokinetic (PPK) model of Chinese pediatric and adult patients with epilepsy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 135 perampanel plasma concentrations from 125 patients with epilepsy were analyzed using the PPK model with nonlinear mixed-effects modeling. One-compartment and proportional residual models best described the pharmacokinetics of perampanel. Covariate effects on the model parameters were assessed using forward and backward elimination. Goodness-of-fit, bootstrapping, visual predictive checks, and normalized prediction distribution errors were used to evaluate the model. Monte Carlo simulations were conducted to assess the impact of covariate combinations on perampanel plasma concentrations at different dosages.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In the final PPK model, body weight (BW), concomitant carbamazepine (CBZ), oxcarbazepine (OXC), and C-reactive protein (CRP) levels significantly influenced perampanel clearance. The interindividual clearance was calculated as follows: 0.84 \u00d7 (BW\/70)<jats:sup>0.53<\/jats:sup> \u00d7 e<jats:sup>CBZ<\/jats:sup> \u00d7 e<jats:sup>OXC<\/jats:sup> \u00d7 e<jats:sup>CRP<\/jats:sup> (CBZ = 0.98, when comedicated with carbamazepine; OXC = 0.43, when comedicated with oxcarbazepine; CRP = \u22120.69, when CRP &gt;15 mg\/L, otherwise = 0). The estimates (relative standard error) for clearance and apparent volume of distribution of the final model were 0.84 L\/h (8.75%) and 64.35 L (19.78%), respectively. The model maintained its stability and effectiveness with moderate predictability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>BW and CBZ, OXC, and CRP levels may influence perampanel clearance in both pediatric and adult patients with epilepsy according to a population pharmacokinetic model that included real-world data.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001296","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T08:03:00Z","timestamp":1738656180000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetics of Perampanel in Chinese Pediatric and Adult Patients With Epilepsy"],"prefix":"10.1097","volume":"47","author":[{"given":"Jiayu","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University ;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitian","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Capital Medical University ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University ;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University ;"},{"name":"Department of Clinical Pharmacology, College of Pharmaceutical Sciences, Capital Medical University ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beijing Children's Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"key":"R2-20250912","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10286-019-00596-x","article-title":"Epidemiology and pathophysiology of autonomic seizures: a systematic review","volume":"29","author":"Baumgartner","year":"2019","journal-title":"Clin Auton Res."},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/jpm13040623","article-title":"State of the art and challenges in epilepsy-a narrative review","volume":"13","author":"Manole","year":"2023","journal-title":"J Pers Med."},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"1403232","DOI":"10.3389\/fphar.2024.1403232","article-title":"Phytotherapeutic options for the treatment of epilepsy: pharmacology, targets, and mechanism of action","volume":"15","author":"Waris","year":"2024","journal-title":"Front Pharmacol."},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14656566.2020.1829594","article-title":"Pharmacological treatment of focal epilepsy in adults: an evidence based approach","volume":"22","author":"Mula","year":"2021","journal-title":"Expert Opin Pharmacother."},{"key":"R6-20250912","doi-asserted-by":"crossref","first-page":"16280","DOI":"10.3390\/ijms242216280","article-title":"Genetic background of epilepsy and antiepileptic treatments","volume":"24","author":"Borowicz-Reutt","year":"2023","journal-title":"Int J Mol Sci."},{"key":"R7-20250912","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.2147\/NDT.S178405","article-title":"An evidence-based review on the use of perampanel for the treatment of focal-onset seizures in pediatric patients","volume":"15","author":"Dozi\u00e8res-Puyravel","year":"2019","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","article-title":"Epilepsy: perampanel-new promise for refractory epilepsy?","volume":"8","author":"L\u00f6scher","year":"2012","journal-title":"Nat Rev Neurol."},{"key":"R9-20250912","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/epi.12865","article-title":"The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist","volume":"56","author":"Patsalos","year":"2015","journal-title":"Epilepsia"},{"key":"R11-20250912","first-page":"683","article-title":"Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy","volume":"41","author":"Greenwood","year":"2016","journal-title":"P T"},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2147\/DDDT.S154388","article-title":"Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelines","volume":"12","author":"Reimers","year":"2018","journal-title":"Drug Des Devel Ther."},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eplepsyres.2016.08.025","article-title":"Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures","volume":"127","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res."},{"key":"R15-20250912","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/ane.12874","article-title":"Pharmacokinetic\/pharmacodynamic analysis of adjunctive perampanel in subjects with partial-onset seizures","volume":"137","author":"Takenaka","year":"2018","journal-title":"Acta Neurol Scand."},{"key":"R16-20250912","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/pharmaceutics15061704","article-title":"Population pharmacokinetic analysis of perampanel in Portuguese patients diagnosed with refractory epilepsy","volume":"15","author":"Silva","year":"2023","journal-title":"Pharmaceutics"},{"key":"R17-20250912","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/epi.17954","article-title":"Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: a real-world study","volume":"65","author":"Li","year":"2024","journal-title":"Epilepsia"},{"key":"R18-20250912","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/FTD.0000000000001055","article-title":"Population pharmacokinetic analysis of drug-drug interactions between perampanel and carbamazepine using enzyme induction model in epileptic patients","volume":"45","author":"Fujita","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R19-20250912","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/jcph.2415","article-title":"Effect of age, comedications, and CYP3A4\/5 polymorphisms on perampanel exposure in Chinese pediatric patients with epilepsy","volume":"64","author":"Wang","year":"2024","journal-title":"J Clin Pharmacol."},{"key":"R20-20250912","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/FTD.0000000000000416","article-title":"Therapeutic drug monitoring for perampanel in Japanese epilepsy patients: influence of concomitant antiepileptic drugs","volume":"39","author":"Yamamoto","year":"2017","journal-title":"Ther Drug Monit."},{"key":"R21-20250912","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/chromsci\/bmaa060","article-title":"Quantification of the plasma concentrations of perampanel using high-performance liquid chromatography and effects of the CYP3A4*1G polymorphism in Japanese patients","volume":"58","author":"Ohkubo","year":"2020","journal-title":"J Chromatogr Sci."},{"key":"R22-20250912","doi-asserted-by":"crossref","first-page":"115437","DOI":"10.1016\/j.jpba.2023.115437","article-title":"Simultaneous determination of 24 antiepileptic drugs and their active metabolites in human plasma by UHPLC-MS\/MS","volume":"232","author":"Jiang","year":"2023","journal-title":"J Pharm Biomed Anal."},{"key":"R23-20250912","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N Engl J Med."},{"key":"R24-20250912","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol."},{"key":"R25-20250912","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med."},{"key":"R26-20250912","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed."},{"key":"R27-20250912","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS J"},{"key":"R28-20250912","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/17425255.2019.1560420","article-title":"Pharmacokinetic and pharmacodynamic considerations for the clinical efficacy of perampanel in focal onset seizures","volume":"15","author":"de Biase","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R29-20250912","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/FTD.0000000000000556","article-title":"Influence of inflammation on the pharmacokinetics of perampanel","volume":"40","author":"Yamamoto","year":"2018","journal-title":"Ther Drug Monit."},{"key":"R30-20250912","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/FTD.0000000000001101","article-title":"Therapeutic drug monitoring of perampanel in children with refractory epilepsy: focus on influencing factors on the free-perampanel concentration","volume":"45","author":"Qu","year":"2023","journal-title":"Ther Drug Monit."},{"key":"R31-20250912","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1111\/epi.14446","article-title":"Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy","volume":"59","author":"Contin","year":"2018","journal-title":"Epilepsia"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:54Z","timestamp":1757678574000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001296","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"2024-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}